Значение кларитромицина в эрадикационнойтерапии инфекции Helicobacter pylori
Значение кларитромицина в эрадикационнойтерапии инфекции Helicobacter pylori
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. Malfertheiner P, Megraud F, O`Morain C et al. Current concept in the management of Helicobacter pylori infection: the Maasticht III Consensus Report. Gut 2007; 56: 772–81.
2. Кудрявцева Л.В. Региональные генотипы и уровни резистентности к антибактериальным препаратам Helicobacter pylori. Автореф. дис. ... д-ра мед. наук. М., 2004.
3. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003; 17 (Suppl. B): 36–40B.
4. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication – the influence of structured counselling and follow-up. Brit J Clin Pharmacol 2002; 53 (2): 163–71.
5. Gatta L, Vakil N, Leandro G et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104 (12): 3069–79.
6. Gustavson LE, Kaiser JF, Edmonds AL et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39 (9): 2078–83.
7. Cole ShP, Harwood J, Lee R et al. Characterization of Monospecies Biofilm Formation by Helicobacter pylori. J Bacteriol 2004; 186: 3124–32.
8. Coticchia JM, Sugawa Ch, Tran VR et al. Presence and Density of Helicobacter pylori Biofilms in Human Gastric Mucosa in Patients With Peptic Ulcer Disease. J Gastrointest Surg 2006; 10: 883–9.
9. Giao MS, Azevedo NF, Wilks SA et al. Persistance of Helicobacter pylori in heterogenic drinking-water biofilms. Appl Environ Microbiol 2008; 74: 5898–904.
10. Sano M, Hirose T, Nishimura M et al. Inhibitory action of clarithromycine on glycocalyx produced by MRSA. J Infect Chemother 1999; 5: 10–5.
11. Yasuda H, Ajiki Yo, Koga T, Yokota T. Interaction between Clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob Ag Chemother 1994; 38: 138–41.
12. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H.pylori eradication rates in clinical practice by adopting first and second line regimens proposed by he Maastricht III consensus and a third line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
PR — RU — ABB – KLA 35 (06/10)
2. Кудрявцева Л.В. Региональные генотипы и уровни резистентности к антибактериальным препаратам Helicobacter pylori. Автореф. дис. ... д-ра мед. наук. М., 2004.
3. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003; 17 (Suppl. B): 36–40B.
4. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication – the influence of structured counselling and follow-up. Brit J Clin Pharmacol 2002; 53 (2): 163–71.
5. Gatta L, Vakil N, Leandro G et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104 (12): 3069–79.
6. Gustavson LE, Kaiser JF, Edmonds AL et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39 (9): 2078–83.
7. Cole ShP, Harwood J, Lee R et al. Characterization of Monospecies Biofilm Formation by Helicobacter pylori. J Bacteriol 2004; 186: 3124–32.
8. Coticchia JM, Sugawa Ch, Tran VR et al. Presence and Density of Helicobacter pylori Biofilms in Human Gastric Mucosa in Patients With Peptic Ulcer Disease. J Gastrointest Surg 2006; 10: 883–9.
9. Giao MS, Azevedo NF, Wilks SA et al. Persistance of Helicobacter pylori in heterogenic drinking-water biofilms. Appl Environ Microbiol 2008; 74: 5898–904.
10. Sano M, Hirose T, Nishimura M et al. Inhibitory action of clarithromycine on glycocalyx produced by MRSA. J Infect Chemother 1999; 5: 10–5.
11. Yasuda H, Ajiki Yo, Koga T, Yokota T. Interaction between Clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob Ag Chemother 1994; 38: 138–41.
12. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H.pylori eradication rates in clinical practice by adopting first and second line regimens proposed by he Maastricht III consensus and a third line empirical regimen. Am J Gastroenterol 2009; 104: 21–5.
PR — RU — ABB – KLA 35 (06/10)
Авторы
Т.Л.Лапина
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.